3Feldtkeller E, Hammel L, Brenneis C, et al. Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany. Z Rheumatol, 2011,70:431-437.
5Kroon F, Landew6 R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis, 2012,71 : 1623-1629.
6Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti- tumor necrosis factor alpha agents. Arthritis Rheum, 2007, 57 : fiO- 647.
7Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing sondylitis results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum, 2008,58:88-97.
8Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther, 2011,27:13 :R105.
8Zink A. Braun J, Listing J, etal. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-resuhs from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol, 2000, 27: 613-622.
9Marzo-Ortega H, Mcgonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum, 2001, 44:2112-2117.
10Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double blind, placebo-controlled trial of etanercept treatment in atients with active ankylosing spondylitis. Arthritis Rheum, 2003, 48: 1667-1675.
6Davis JC Jr,van der Heijde DM,Dougados M. Baseline factors thai influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept[J].{H}Journal of Rheumatology,2005.1751-1754.
7Arends S,Brouwer E,van der Veer E. Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis:a prospective lmgitudinal observational cohort study[J].{H}Arthritis Research & Therapy,2011.R94.
8Glintborg B,Ostergaard M,Krogh NS. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with antitumour necrosis factor:results from 8 years' surveillance in the Danish nationwide DANBIO registry[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2010.2002-2008.
9Poddubnyy DA,Rudwaleit M,Listing J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2010.1338-1341.
10Brandt J,listing J,Haibel H. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis[J].{H}RHEUMATOLOGY,2005.342-348.
